Phase 3 ELOQUENT-2 study extended 5-y follow-up comparing elotuzumab plus lenalidomide/dexamethasone (ELd) with Ld to treat relapsed/refractory multiple myeloma

被引：0

作者：

Weisel, K. ^{[1
]}

Dimopoulos, M. A. ^{[2
]}

Lonial, S. ^{[3
]}

White, D. ^{[4
,5
]}

Moreau, P. ^{[6
]}

Mateos, M-, V ^{[7
]}

San Miguel, J. ^{[8
]}

Anderson, K. ^{[9
]}

Shpilberg, O. ^{[10
]}

Grosicki, S. ^{[11
]}

Spicka, I ^{[12
,13
]}

Walter-Cronek, A. ^{[14
]}

Magen, H. ^{[15
]}

Belch, A. ^{[16
,17
]}

Reece, D. ^{[18
]}

Beksac, M. ^{[19
]}

Shelat, S. G. ^{[20
]}

Mekan, S. ^{[20
]}

Sy, O. ^{[20
]}

Singhal, A. K. ^{[21
]}

Richardson, P. G. ^{[9
]}

机构：

[1] Univ Tubingen, Tubingen, Germany

[2] Univ Athens, Sch Med, Athens, Greece

[3] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[4] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada

[5] Dalhousie Univ, Halifax, NS, Canada

[6] Univ Hosp, Nantes, France

[7] Univ Hosp Salamanca, Inst Invest Biomed Salamanca IBSAL, Salamanca, Spain

[8] Clin Univ Navarra, Ctr Invest Med Aplicada, IDISNA, CIBERONC, Pamplona, Spain

[9] Dana Farber Canc Inst, Boston, MA 02115 USA

[10] Assuta Med Ctr, Inst Haematol, Tel Aviv, Israel

[11] Med Univ Silesia, Katowice, Poland

[12] Charles Univ Prague, Prague, Czech Republic

[13] Gen Teaching Hosp, Prague, Czech Republic

[14] Med Univ Lublin, Lublin, Poland

[15] Sheba Med Ctr Hosp Tel HaShomer, Ramat Gan, Israel

[16] Cross Canc Inst, Edmonton, AB, Canada

[17] Univ Alberta, Edmonton, AB, Canada

[18] Princess Margaret Hosp, Toronto, ON, Canada

[19] Ankara Univ, Ankara, Turkey

[20] Bristol Myers Squibb, Princeton, NJ USA

[21] AbbVie Inc, Redwood City, CA USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V692

引用

页码：230 / 230

页数：1